Latest news
Buy Rating Reiterated on Sobi as Diversified Pipeline and Lacutamab Partnership Support Upside; 12‑Month SEK575 Price Target Unchanged - TipRanksTipRanks · Mon, 10 Aug 2026 16:38:51 GMTSwedish kiss for french Innate: Sobi backs Innate’s lacutamab as rare T-cell lymphoma program enters Phase 3 - European Biotechnology MagazineEuropean Biotechnology Magazine · Mon, 10 Aug 2026 14:03:09 GMTM&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo - Pharmaceutical ExecutivePharmaceutical Executive · Mon, 10 Aug 2026 13:57:46 GMTSobi pens $580M deal for Innate’s cancer drug before ph. 3 push - Fierce BiotechFierce Biotech · Mon, 10 Aug 2026 11:13:48 GMTSobi adds rare lymphoma drug with $580m Innate tie-up - pharmaphorumpharmaphorum · Mon, 10 Aug 2026 10:15:01 GMTInnate Pharma (NASDAQ: IPHA) secures Sobi deal, $75M upfront and Phase 3 push - Stock TitanStock Titan · Mon, 10 Aug 2026 10:05:10 GMTSobi partners with Innate Pharma to advance lac... - PluangPluang · Mon, 10 Aug 2026 07:32:30 GMTSobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma - Yahoo! Finance CanadaYahoo! Finance Canada · Mon, 10 Aug 2026 06:36:00 GMT